

Contains Nonbinding Recommendations

Draft – Not for Implementation

Marketing Submission Recommendations for a Predetermined Change Control Plan for Artificial Intelligence/Machine Learning (AI/ML)-Enabled Device Software Functions

Draft Guidance for Industry and Food and Drug Administration Staff

DRAFT GUIDANCE

This draft guidance document is being distributed for comment purposes only.

Document issued on April 3, 2023.

You should submit comments and suggestions regarding this draft document within 90 days of publication in the *Federal Register* of the notice announcing the availability of the draft guidance. Submit electronic comments to <https://www.regulations.gov>. Submit written comments to the Dockets Management Staff, Food and Drug Administration, 5630 Fishers Lane, Room 1061, (HFA-305), Rockville, MD 20852. Identify all comments with the docket number listed in the notice of availability that publishes in the *Federal Register*.

For questions about this document regarding CDRH-regulated devices, contact digitalhealth@fda.hhs.gov. For questions about this document regarding CBER-regulated devices, contact ocod@fda.hhs.gov. For questions about this document regarding CDER-regulated products, contact druginfo@fda.hhs.gov. For questions about this document regarding combination products, contact the Office of Combination Products at combination@fda.gov.



U.S. Department of Health and Human Services
Food and Drug Administration
Center for Devices and Radiological Health
Center for Biologics Evaluation and Research
Center for Drug Evaluation and Research
Office of Combination Products in the Office of the Commissioner

Contains Nonbinding Recommendations

Draft – Not for Implementation

Preface

Additional Copies

CDRH

Additional copies are available from the Internet. You may also send an email request to CDRH-Guidance@fda.hhs.gov to receive a copy of the draft guidance. Please include the document number GUI00020049 and complete title of the guidance in the request.

CBER

Additional copies are available from the Center for Biologics Evaluation and Research (CBER), Office of Communication, Outreach, and Development (OCOD), 10903 New Hampshire Ave., Bldg. 71, Room 3128, Silver Spring, MD 20993-0002, or by calling 1-800-835-4709 or 240-402-8010, by email, ocod@fda.hhs.gov, or from the Internet at <https://www.fda.gov/vaccines-blood-biologics/guidance-compliance-regulatory-information-biologics/biologics-guidances>.

CDER

Additional copies are available from the Center for Drug Evaluation and Research, Office of Communications, Division of Drug Information, 10001 New Hampshire Ave., Hillendale Bldg., 4th Floor, Silver Spring, MD 20993-0002, or by calling 855-543-3784 or 301-796-3400, or by email, druginfo@fda.hhs.gov, or from the Internet at <https://www.fda.gov/drugs/guidance-compliance-regulatory-information/guidances-drugs>.

Contains Nonbinding Recommendations

Draft – Not for Implementation

Table of Contents

I.	Introduction.....	1
II.	Background.....	2
III.	Scope.....	5
IV.	Definitions.....	8
A.	Software Functions.....	8
B.	Data Sets.....	8
C.	Predetermined Change Control Plan.....	9
V.	Policy for Predetermined Change Control Plans.....	9
A.	Components of a PCCP.....	10
B.	Establishing a PCCP.....	11
C.	Identifying a PCCP in a Marketing Submission.....	12
D.	Utilizing an Authorized PCCP to Implement Device Modifications.....	13
E.	Modifying a PCCP for an Authorized Device.....	15
VI.	Description of Modifications.....	16
A.	Goals of the Description of Modifications Section.....	16
B.	Content of the Description of Modifications Section.....	16
C.	Types of Modifications.....	17
VII.	Modification Protocol.....	18
A.	Goals of the Modification Protocol Section.....	18
B.	Content of the Modification Protocol Section.....	20
(1)	Data management practices.....	20
(2)	Re-training practices.....	21
(3)	Performance evaluation.....	22
(4)	Update procedures.....	22
C.	Traceability Between the Description of Modifications Section and the Modification Protocol Section.....	23
VIII.	Impact Assessment.....	24
Appendix A:	Example Elements of Modification Protocol Components for ML-DSFs.....	26
(1)	Data Management.....	26
(2)	Re-Training.....	28
(3)	Performance Evaluation.....	29

Contains Nonbinding Recommendations

Draft – Not for Implementation

(4) Update Procedures	30
Appendix B: Example ML-DSF Scenarios Employing PCCPs	33
(1) Patient Monitor Software.....	33
(2) Skin Lesion Software.....	35
(3) Ventilator Settings Software.....	36
(4) Image Acquisition Assistance Device	37
(5) Feeding Tube Placement Radiograph Analysis Software	38

DRAFT

1 **Marketing Submission**
2 **Recommendations for a**
3 **Predetermined Change Control Plan**
4 **for Artificial Intelligence/Machine**
5 **Learning (AI/ML)-Enabled Device**
6 **Software Functions**

8 **Draft Guidance for Industry and**
9 **Food and Drug Administration Staff**

11 *This draft guidance, when finalized, will represent the current thinking of the Food and Drug*
12 *Administration (FDA or Agency) on this topic. It does not establish any rights for any person*
13 *and is not binding on FDA or the public. You can use an alternative approach if it satisfies the*
14 *requirements of the applicable statutes and regulations. To discuss an alternative approach,*
15 *contact the FDA staff or Office responsible for this guidance as listed on the title page.*

17 **I. Introduction**

18 FDA has a longstanding commitment to develop and apply innovative approaches to the
19 regulation of medical device software and other digital health technologies to ensure their safety
20 and effectiveness.¹ As technology continues to advance all facets of healthcare, medical software
21 incorporating artificial intelligence (AI), and specifically the subset of AI known as machine
22 learning (ML) (henceforth referred to as machine learning-enabled device software functions or
23 ML-DSFs), has become an important part of many medical devices. This draft guidance is

¹ FDA regulates software that meets the definition of a device, which is defined in section 201(h)(1) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) as “an instrument, apparatus, implement, machine, contrivance, implant, in vitro reagent, or other similar or related article, including any component, part, or accessory, which is – recognized in the official National Formulary, or the United States Pharmacopoeia, or any supplement to them, intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment, or prevention of disease, in man or other animals, or intended to affect the structure or any function of the body of man or other animals, and which does not achieve its primary intended purposes through chemical action within or on the body of man or other animals and which is not dependent upon being metabolized for the achievement of its primary intended purposes. The term ‘device’ does not include software functions excluded pursuant to section 520(o)” of the FD&C Act.

Contains Nonbinding Recommendations

Draft – Not for Implementation

24 intended to provide a forward-thinking approach to promote the development of safe and
25 effective medical devices that use ML models trained by ML algorithms.

26
27 ML-enabled technologies have the potential to transform healthcare by deriving new and
28 important insights from the vast amount of data generated during the delivery of healthcare every
29 day. Medical device manufacturers² are using ML technologies to innovate their products to
30 better assist healthcare providers and improve patient care. Examples of ML applications in
31 medicine include earlier disease detection and diagnosis, development of personalized
32 diagnostics and therapeutics, and development of assistive functions to improve the use of
33 devices with the goal of improving user and patient experience.

34
35 FDA recognizes that the development of ML-DSFs is an iterative process. This draft guidance
36 proposes a least burdensome approach to support iterative improvement through modifications to
37 an ML-DSF while continuing to provide a reasonable assurance of device safety and
38 effectiveness. As such, this draft guidance demonstrates FDA’s broader commitment to
39 developing innovative approaches to the regulation of device software functions as a whole.
40 Specifically, this draft guidance provides recommendations on the information to be included in
41 a Predetermined Change Control Plan (PCCP) provided in a marketing submission for an ML-
42 DSF. This draft guidance recommends that a PCCP describe the planned ML-DSF
43 modifications; the associated methodology to develop, implement, and validate³ those
44 modifications; and an assessment of the impact of those modifications. The PCCP is reviewed as
45 part of a marketing submission to ensure the continued safety and effectiveness of the device
46 without necessitating additional marketing submissions for implementing each modification
47 described in the PCCP.

48
49 In general, FDA’s guidance documents do not establish legally enforceable responsibilities.
50 Instead, guidances describe the Agency’s current thinking on a topic and should be viewed only
51 as recommendations, unless specific regulatory or statutory requirements are cited. The use of
52 the word *should* in Agency guidances means that something is suggested or recommended, but
53 not required.

54

55 **II. Background**

56 In April 2019, FDA published the [Proposed Regulatory Framework for Modifications to](#)
57 [Artificial Intelligence/Machine Learning \(AI/ML\)-Based Software as a Medical Device \(SaMD\)](#)

² For the purposes of this guidance, “manufacturer” is used in accordance with the definitions of manufacturer in 21 CFR Parts 803, 806, 807, and 820 and as described in FDA’s guidance “Policy for Device Software Functions and Mobile Medical Applications” (DSF-MMA) available at <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/policy-device-software-functions-and-mobile-medical-applications>.

³ For the purposes of this guidance, the term “validation” is being used as it is defined in 21 CFR 820.3(z), which states “[v]alidation means confirmation by examination and provision of objective evidence that the particular requirements for a specific intended use can be consistently fulfilled.” See Section IV. for more information on definitions used for the purposes of this guidance.

Contains Nonbinding Recommendations

Draft – Not for Implementation

58 [- Discussion Paper and Request for Feedback](#) (“2019 discussion paper”).⁴ The 2019 discussion
59 paper describes FDA’s foundation for a potential approach to premarket review for AI/ML-
60 driven software modifications. The ideas delineated in the 2019 discussion paper leveraged
61 practices from our current premarket programs and relied on the [International Medical Device](#)
62 [Regulators Forum’s risk categorization principles](#),⁵ the FDA’s benefit-risk framework,⁶ risk
63 management principles described in the [Software Modifications guidance](#),⁷ and the total product
64 lifecycle approach envisioned in the [Digital Health Software Precertification \(Pre-Cert\) Pilot](#)
65 [Program](#).⁸
66

67 ML can allow software to learn through data, without being explicitly programmed, to perform a
68 task. One of the greatest potential benefits of ML resides in the ability to improve ML model
69 performance through iterative modifications, including by learning from real-world data. To
70 support the iterative development of ML-DSFs, and as part of the proposed framework presented
71 in the 2019 discussion paper, FDA described a “Predetermined Change Control Plan” that could
72 be included in a marketing submission for a device that is or includes an ML-DSF (referred to
73 interchangeably as an “ML-DSF” or a “device”).⁹ In this draft guidance, we provide
74 recommendations on the marketing submission content for a PCCP, which generally includes: 1)
75 a detailed description of the specific, planned device modifications; 2) the associated
76 methodology to develop, validate, and implement those modifications in a manner that ensures
77 the continued safety and effectiveness of the device across relevant patient populations, referred
78 to as the “Modification Protocol”; and 3) an Impact Assessment to describe the assessment of the
79 benefits and risks of the planned modifications and risk mitigations.
80

81 The 2019 discussion paper received a substantial amount of feedback from a wide array of
82 stakeholders. General comments were received, as well as specific responses to 18 questions

⁴ Available at <https://www.fda.gov/medical-devices/software-medical-device-samd/artificial-intelligence-and-machine-learning-software-medical-device>.

⁵ See FDA’s website on “Global Approach to Software as a Medical Device” available at <https://www.fda.gov/medical-devices/software-medical-device-samd/global-approach-software-medical-device> and IMDRF’s SaMD Risk Categorization Framework available at <http://www.imdrf.org/docs/imdrf/final/technical/imdrf-tech-140918-samd-framework-risk-categorization-141013.pdf>.

⁶ See FDA’s guidance “Factors to Consider When Making Benefit-Risk Determinations in Medical Device Premarket Approval and De Novo Classifications” available at <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/factors-consider-when-making-benefit-risk-determinations-medical-device-premarket-approval-and-de> and FDA’s guidance “Benefit-Risk Factors to Consider When Determining Substantial Equivalence in Premarket Notifications (510(k)) with Different Technological Characteristics” available at <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/benefit-risk-factors-consider-when-determining-substantial-equivalence-premarket-notifications-510k>.

⁷ See FDA’s guidance “Deciding When to Submit a 510(k) for a Software Change to an Existing Device” available at <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/deciding-when-submit-510k-software-change-existing-device>.

⁸ See FDA’s website on “Digital Health Software Precertification (Pre-Cert) Program” available at <https://www.fda.gov/medical-devices/digital-health-center-excellence/digital-health-software-precertification-pre-cert-program>.

⁹ For the purposes of this guidance, the terms “ML-DSF” and “device” are used interchangeably. Additionally, reference to an “ML-DSF” is referring to a software function that meets the definition of device, as defined in section 201(h) of the FD&C Act. See Section IV. for details on definitions.

Contains Nonbinding Recommendations

Draft – Not for Implementation

83 posed in the 2019 discussion paper.¹⁰ Additionally, numerous articles in peer-reviewed journals
84 discuss or reference the framework proposed in the 2019 discussion paper.¹¹

85
86 FDA has also held a number of public meetings and workshops on AI/ML topics. On February
87 25-26, 2020, FDA held a [Public Workshop on the “Evolving Role of Artificial Intelligence in
88 Radiological Imaging”](#)¹² to discuss emerging applications of AI in radiological imaging,
89 including AI devices intended to automate the diagnostic radiology workflow as well as guide
90 image acquisition. At this workshop, the Agency worked with interested stakeholders, including
91 patients, to identify both benefits and risks associated with the use of AI in radiological imaging,
92 and discussed best practices for the validation of fully automated radiological imaging software
93 and image acquisition devices.

94
95 On October 22, 2020, FDA held a [Patient Engagement Advisory Committee meeting on
96 “Artificial Intelligence and Machine Learning in Medical Devices”](#)¹³ to further elicit input from a
97 diverse group of patients on AI/ML technologies. The Committee provided recommendations on
98 AI/ML-enabled medical devices and how to foster patient trust in them, considering the diverse
99 populations in which they are and will be used.

100
101 On October 14, 2021, FDA held a [Public Workshop on “Transparency of Artificial
102 Intelligence/Machine Learning-enabled Medical Devices”](#)¹⁴ for patients, caregivers, and
103 providers. The purpose of the workshop was to 1) identify unique considerations in achieving
104 transparency for users of AI/ML-enabled medical devices and ways in which transparency might
105 enhance the safety and effectiveness of these devices; and 2) gather input from various
106 stakeholders on the types of information that would be helpful for manufacturers to include in
107 the labeling and public facing information of AI/ML-enabled medical devices, as well as other
108 potential mechanisms for information sharing.

109
110 FDA continues to receive an increasing number of marketing submissions and pre-submissions
111 for devices leveraging ML technologies, and the Agency expects this to increase over time.
112 Moreover, since the 2019 discussion paper’s publication, there has been strong interest in
113 utilizing PCCPs for AI/ML-enabled medical devices.

114
115 In light of the public health need to facilitate innovation for ML-DSFs while providing
116 appropriate oversight for them, on January 12, 2021, the CDRH Digital Health Center of

¹⁰ For more information, see the 2019 discussion paper’s public docket available at <https://www.regulations.gov/document/FDA-2019-N-1185-0001>.

¹¹ For example, Gerke S et al., “The need for a system view to regulate artificial intelligence/machine learning-based software as medical device,” NPJ Digit Med 3, 53 (2020); Harvey et al., “How the FDA Regulates AI,” Academic Radiology 27, 58-61 (2020); and Subbaswamy et al., “From development to deployment: dataset shift, causality, and shift-stable models in health AI,” Biostatistics 21, 345-352 (2020).

¹² Available at <https://www.fda.gov/medical-devices/workshops-conferences-medical-devices/public-workshop-evolving-role-artificial-intelligence-radiological-imaging-02252020-02262020>.

¹³ Available at <https://www.fda.gov/advisory-committees/advisory-committee-calendar/october-22-2020-patient-engagement-advisory-committee-meeting-announcement-10222020-10222020>.

¹⁴ Available at <https://www.fda.gov/medical-devices/workshops-conferences-medical-devices/virtual-public-workshop-transparency-artificial-intelligencemachine-learning-enabled-medical-devices>.

Contains Nonbinding Recommendations

Draft – Not for Implementation

117 Excellence issued FDA’s [Artificial Intelligence/Machine Learning \(AI/ML\)-Based Software as a](#)
118 [Medical Device Action Plan](#) (“the Action Plan”).¹⁵ The Action Plan describes FDA’s strategy for
119 addressing AI/ML-enabled medical devices in a holistic, collaborative, and multidisciplinary
120 manner. An important pillar of the Action Plan is the further advancement of the tailored
121 regulatory framework for ML-enabled medical devices that was proposed in the 2019 discussion
122 paper.

123
124 Further, on October 4, 2022, the White House released a [Blueprint for an AI Bill of Rights](#),¹⁶
125 which outlined five principles that should guide the design, use, and deployment of automated
126 systems. These five principles discuss: safe and effective systems; algorithmic discrimination
127 protections; data privacy; notice and explanation; and human alternatives, consideration, and
128 fallback. This draft guidance is consistent with and promotes the principles described in the
129 Blueprint for an AI Bill of Rights.

130
131 Additionally, section 3308 of the Food and Drug Omnibus Reform Act of 2022, Title III of
132 Division FF of the Consolidated Appropriations Act, 2023, Pub. L. No. 117-328 (“FDORA”),
133 enacted on December 29, 2022, added section 515C “Predetermined Change Control Plans for
134 Devices” to the FD&C Act. Section 515C provides FDA with express authority to approve or
135 clear PCCPs for devices requiring premarket approval or premarket notification. For example,
136 section 515C provides that supplemental applications (section 515C(a)) and new premarket
137 notifications (section 515C(b)) are not required for a change to a device that would otherwise
138 require a premarket approval supplement or new premarket notification if the change is
139 consistent with a PCCP previously approved or cleared by FDA. Section 515C also provides that
140 FDA may require that a PCCP include labeling for safe and effective use of a device as such
141 device changes pursuant to such plan, notification requirements if the device does not function as
142 intended pursuant to such plan, and performance requirements for changes made under the
143 plan.¹⁷ In this draft guidance, we provide recommendations on the marketing submission content
144 for PCCPs, which are based on the statute and feedback obtained through our various
145 interactions with stakeholders.

147 **III. Scope**

148 This draft guidance is applicable to ML-DSFs that the manufacturer intends to modify over time.
149 This includes ML-DSFs for which modifications to the ML model are implemented
150 automatically (i.e., for which the modifications are implemented automatically by software), as
151 well as for ML-DSFs for which modifications to the ML model are implemented manually (i.e.,
152 involving steps that require human input, action, review, and/or decision-making, and therefore
153 are not implemented automatically).

154

¹⁵ Available at <https://www.fda.gov/medical-devices/software-medical-device-samd/artificial-intelligence-and-machine-learning-software-medical-device>.

¹⁶ Available at <https://www.whitehouse.gov/ostp/ai-bill-of-rights/>.

¹⁷ Sections 515C(a)(3) and (b)(3) of the FD&C Act.

Contains Nonbinding Recommendations

Draft – Not for Implementation

155 This draft guidance describes an approach that would often be least burdensome and would
156 support the ability to modify an ML-DSF while continuing to provide a reasonable assurance of
157 safety and effectiveness across relevant patient populations. Specifically, this draft guidance
158 proposes recommendations on the information to be included in the PCCP in a marketing
159 submission¹⁸ for a device that is or includes an ML-DSF. For the purposes of this guidance, the
160 term “PCCP” refers to a plan that includes device modifications that would otherwise require a
161 premarket approval supplement, De Novo submission, or a new premarket notification. A plan
162 that contains only minor modifications that would not require a new submission is outside the
163 scope of this guidance. For more information on whether a modification would require a new
164 submission, see [Deciding When to Submit a 510\(k\) for a Software Change to an Existing Device](#)¹⁹ and [Deciding When to Submit a 510\(k\) for a Change to an Existing Device](#)²⁰ or
165 [Modifications to Devices Subject to Premarket Approval \(PMA\) - The PMA Supplement Decision-Making Process](#)²¹ guidances. Throughout this guidance, a PCCP that has been
166 reviewed and established through a device marketing authorization is also referred to as an
167 “authorized PCCP.” See Section IV. for more information on definitions used for the purposes of
168 this guidance.
169
170

171
172 By including a PCCP in a marketing submission, manufacturers can proactively pre-specify and
173 seek premarket authorization²² for intended modifications (and their method of implementation)
174 to an ML-DSF without necessitating additional marketing submissions for each modification
175 delineated and implemented in accordance with the PCCP. In other words, a PCCP, as part of a
176 marketing submission, is intended to provide a means to implement modifications to an ML-DSF
177 that generally would otherwise require additional marketing submissions prior to
178 implementation.²³
179

180 Modifications to an ML-DSF that could significantly affect,²⁴ or that could affect,²⁵ the safety or
181 effectiveness of the device, unless those modifications are covered by a PCCP, require premarket
182 authorization.²⁶ Premarket authorization for an ML-DSF with a PCCP may be established

¹⁸ For purposes of this guidance, unless otherwise stated, the term “marketing submission” includes premarket notification (510(k)) submission, De Novo Classification request, and Premarket Approval (PMA) application.

¹⁹ Available at <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/deciding-when-submit-510k-software-change-existing-device>.

²⁰ Available at <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/deciding-when-submit-510k-change-existing-device>.

²¹ Available at <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/modifications-devices-subject-premarket-approval-pma-pma-supplement-decision-making-process>.

²² For the purposes of this guidance, the term “authorization” includes clearance of a 510(k) submission, grant of a De Novo Classification request, or approval of a PMA application.

²³ 21 CFR 807.81(a)(3) and 21 CFR 814.39(a).

²⁴ 21 CFR 807.81(a)(3).

²⁵ 21 CFR 814.39(a).

²⁶ In accordance with 21 CFR 807.81(a)(3), a 510(k) is required for significant changes or modifications to a device and include 1) those that “could significantly affect the safety or effectiveness of the device, e.g., a significant change or modification in design, material, chemical composition, energy source, or manufacturing process” or include 2) “a major change or modification in the intended use of the device.” In accordance with 21 CFR 814.39(a), a PMA supplement is required for “change[s] affecting the safety or effectiveness of the device” unless an exception

Contains Nonbinding Recommendations

Draft – Not for Implementation

183 through the 510(k) pathway (see section 515C(b) of the FD&C Act), PMA pathway (see section
184 515C(a) of the FD&C Act), or the De Novo pathway (see section 513(f)(2) of the FD&C Act).²⁷
185 FDA considers the PCCP to be part of the technological characteristics of the device. For devices
186 subject to 510(k) requirements, the determination of substantial equivalence includes, among
187 other requirements, a comparison of the technological characteristics of the predicate device to
188 the technological characteristics of the subject device.²⁸ In making a determination of substantial
189 equivalence where the predicate device was authorized with a PCCP, the subject device must be
190 compared to the version of the predicate device cleared or approved prior to changes made under
191 the PCCP.²⁹

192
193 Generally, the recommendations in this guidance apply to the device constituent part of a
194 combination product³⁰ (such as drug-device and biologic-device combination products) when the
195 device constituent part³¹ is or includes an ML-DSF. Early engagement with the appropriate
196 CBER or CDER Divisions is recommended for drug-device and biologic-device combination
197 products that include an ML-DSF.³² For more information, contact the FDA review division that
198 will have the lead review for the combination product.

199
200 FDA encourages early engagement regarding a proposed PCCP with the FDA review division
201 that will review the ML-DSF; in particular, early engagement could be especially helpful for
202 certain ML-DSFs, including combination products and high-risk, life-sustaining, life-supporting,
203 or implantable devices. FDA encourages manufacturers to leverage the Q-Submission process
204 for obtaining FDA feedback on a proposed PCCP for an ML-DSF.³³

205
206 This draft guidance is not intended to provide a complete description of what may be necessary
207 to include in a marketing submission for an ML-DSF. It is also not intended to delineate the
208 types of modifications the Agency would consider acceptable in a PCCP. However, some
209 considerations on modification types are described, including examples of questions for

applies (see 21 CFR 814.39). For simplicity, in this guidance, we state “significantly” affect the safety or effectiveness of the device” for when a marketing submission may be required, “significant” modifications, and similar phrasings, aligning with 21 CFR 807.81(a)(3). However, for devices subject to PMA requirements, the broader requirement pursuant to 21 CFR 814.39(a) of a “change affecting the safety or effectiveness” applies.

²⁷ The De Novo classification process allows FDA to classify a device into class I or II when general controls or general controls and special controls provide a reasonable assurance of safety and effectiveness, but for which there is no legally marketed predicate. The De Novo pathway, therefore, allows FDA to develop special controls that provide a reasonable assurance of the safety and effectiveness. At this time, FDA expects that if it authorizes an ML-DSF with a PCCP via the De Novo pathway, the Agency would develop appropriate special controls, which may include specific requirements for a PCCP.

²⁸ See section 513(i) of the FD&C Act.

²⁹ See section 515C(c) of the FD&C Act.

³⁰ 21 CFR 3.2(e).

³¹ 21 CFR 4.2.

³² See FDA’s guidance “Requesting FDA Feedback on Combination Products” available at

<https://www.fda.gov/regulatory-information/search-fda-guidance-documents/requesting-fda-feedback-combination-products>.

³³ See FDA’s guidance “Requests for Feedback and Meetings for Medical Device Submissions: The Q-Submission Program” available at <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/requests-feedback-and-meetings-medical-device-submissions-q-submission-program>.

Contains Nonbinding Recommendations

Draft – Not for Implementation

210 consideration that manufacturers should address in a Modification Protocol (see [Appendix A](#))
211 and illustrations of different ML-DSF scenarios where a PCCP could be employed (see
212 [Appendix B](#)). The FDA review division with purview over the device under review will
213 determine the acceptability of a proposed PCCP. That is, the FDA review division will determine
214 whether the scope of the modifications is appropriate for inclusion in a PCCP and what evidence
215 and information are required to support proposed modifications in a marketing submission.³⁴
216

217 IV. Definitions

218 This section defines certain terms as they are used for the purposes of this guidance.

219 A. Software Functions

220 **Device Software Function (DSF):** A software function that meets the device definition in
221 section 201(h) of the FD&C Act.^{35,36} As discussed in other FDA guidances, the term “function”
222 is a distinct purpose of the product, which could be the intended use or a subset of the intended
223 use of the product.³⁷
224

225 **Machine Learning-Enabled Device Software Function (ML-DSF):** A device software
226 function (as defined above) that implements an ML model trained with ML techniques.
227

228 B. Data Sets

229 **Training Data:** These data are used by the ML-DSF manufacturer in procedures and ML
230 training algorithms to build an ML model, including to define model weights, connections, and
231 components. Training the ML model happens after the exploratory phase of ML-DSF
232 development. These data typically should be representative of the proposed intended use
233 populations (e.g., with respect to race, ethnicity, disease severity, gender, age, etc.). The result is
234 an operational ML-DSF.
235

236 **Tuning Data:** These data are typically used by the ML-DSF manufacturer to evaluate a small
237 number of trained ML-DSFs in order to explore, for example different architectures or
238 hyperparameters. The tuning phase is the last phase before ML-DSF testing and is often
239 considered part of the training process. The ML community sometimes refers to the tuning data
240 and phase with the word “validation.” However, we recommend that the word “validation” not

³⁴ 21 CFR 807.81(a)(3) and 21 CFR 814.39(a).

³⁵ See footnote 1.

³⁶ Device software functions may include Software as a Medical Device (SaMD) and Software in a Medical Device (SiMD). See FDA’s website on “Software as a Medical Device (SaMD),” available at <https://www.fda.gov/medical-devices/digital-health-center-excellence/software-medical-device-samd>.

³⁷ See FDA’s guidance “Multiple Function Device Products: Policy and Considerations” available at <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/multiple-function-device-products-policy-and-considerations>.

Contains Nonbinding Recommendations

Draft – Not for Implementation

241 be used when referring to data or operations related to training or tuning ML models intended for
242 medical applications.³⁸

243
244 **Testing Data:** These data are used to characterize the performance of the ML-DSF. The testing
245 phase is expected to provide data to establish a reasonable assurance of safety and effectiveness
246 before an ML-DSF is marketed. Testing data should be independent of data used for training and
247 tuning and should be from multiple sites different from those that were used to generate training
248 and tuning data.

249

250 **C. Predetermined Change Control Plan**

251 **Predetermined Change Control Plan (PCCP):** The documentation describing what
252 modifications will be made to the ML-DSF and how the modifications will be assessed. The
253 modifications described in the PCCP include device changes that would otherwise require a
254 PMA supplement, De Novo submission, or new 510(k) notification. The PCCP includes a
255 Description of Modifications, Modification Protocol, and Impact Assessment.

256 **Authorized Predetermined Change Control Plan (Authorized PCCP):** A PCCP that has been
257 reviewed and established through a device marketing authorization. An authorized PCCP is a
258 technological characteristic of the authorized device with which it was established.

259 **Modification Protocol:** The documentation describing the methods that will be followed when
260 developing, validating, and implementing modifications delineated in the Description of
261 Modifications section of the PCCP. The Modification Protocol includes the verification and
262 validation activities (including pre-defined acceptance criteria) for those modifications and is
263 intended to provide a step-by-step delineation of how the modifications proposed in the PCCP
264 will be implemented while ensuring the device remains safe and effective.

265 **Impact Assessment:** The documentation of the assessment of the benefits and risks of
266 implementing a proposed PCCP, as well as the plan for risk mitigation. It could be a separate
267 section of a PCCP or incorporated into the Modification Protocol, whichever is least burdensome
268 for a particular marketing submission.

269

270 **V. Policy for Predetermined Change Control Plans**

271 Software development is an iterative process, and FDA appreciates that manufacturers of device
272 software functions strive to continually improve and update their devices. Manufacturers should
273 evaluate the impact of modifications to their devices and must submit a marketing submission
274 when device modifications affect the intended use of the device or could significantly affect the
275 safety or effectiveness of the device.³⁹

³⁸ The way the term “validation” is used in the ML community to refer to training or tuning data sets is not consistent with the broad understanding of the word “validation,” defined in 21 CFR 820.3(z) as “confirmation by examination and provision of objective evidence that the particular requirements for a specific intended use can be consistently fulfilled.”

³⁹ 21 CFR 807.81(a)(3) and 21 CFR 814.39(a).

Contains Nonbinding Recommendations

Draft – Not for Implementation

276 An authorized PCCP specifies planned modifications that, if not included in a PCCP, could
277 otherwise require a new marketing submission pursuant to 21 CFR 807.81(a)(3) and 21 CFR
278 814.39(a), and in accordance with [Deciding When to Submit a 510\(k\) for a Software Change to](#)
279 [an Existing Device](#)⁴⁰ and [Deciding When to Submit a 510\(k\) for a Change to an Existing](#)
280 [Device](#)⁴¹ or [Modifications to Devices Subject to Premarket Approval \(PMA\) - The PMA](#)
281 [Supplement Decision-Making Process](#)⁴² guidances (hereafter referred to as the “device
282 modifications guidances”). An authorized PCCP includes the “range of FDA-authorized
283 specifications” for the characteristics and performance of the planned modifications to the device
284 (as part of the detailed Description of Modifications section included in the PCCP), along with
285 the associated verification and validation testing and acceptance criteria to assure the device
286 remains safe and effective across relevant patient populations (as part of the Modification
287 Protocol section included in the PCCP), and documentation of the assessment of the benefits and
288 risks of implementing a proposed PCCP (which could be a separate Impact Assessment section
289 of a PCCP or incorporated into the Modification Protocol). Because modifications made to an
290 ML-DSF in accordance with an authorized PCCP were reviewed and authorized through the
291 marketing submission containing the PCCP, the modifications can be implemented to the ML-
292 DSF without triggering the need for a new marketing submission under 21 CFR 807.81(a)(3) and
293 21 CFR 814.39(a), and in accordance with the device modifications guidances.

294
295 Deviations from the authorized PCCP reviewed in the marketing submission could significantly
296 affect the safety or effectiveness of the device. For example, when implementing a modification
297 that is a deviation from the PCCP, the device’s clinical functionality or performance
298 specifications could be compromised. Deviations from the PCCP include instances where the
299 PCCP is not followed or cannot be followed (e.g., issues related to the Modification Protocol,
300 such as data management, re-training, or performance failure). Accordingly, modifications made
301 to an ML-DSF that are not specified in, or implemented in accordance with, the authorized
302 PCCP (i.e., the manufacturer deviates from the authorized PCCP when implementing the
303 modification) likely require a new marketing submission.^{43, 44} In such a circumstance, continued
304 distribution of the ML-DSF without submitting a new marketing submission would constitute
305 adulteration and misbranding under sections 501(f)(1)(B) and 502(o) of the FD&C Act,
306 respectively. Adulteration and misbranding are prohibited acts under section 301 of the FD&C
307 Act, and where appropriate, FDA may take legal or regulatory action against violations of
308 prohibited acts, including, without limitation, seizure or injunction.

309

310 **A. Components of a PCCP**

⁴⁰ Available at <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/deciding-when-submit-510k-software-change-existing-device>.

⁴¹ Available at <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/deciding-when-submit-510k-change-existing-device>.

⁴² Available at <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/modifications-devices-subject-premarket-approval-pma-pma-supplement-decision-making-process>.

⁴³ 21 CFR 807.81(a)(3) and 21 CFR 814.39(a).

⁴⁴ See Section V.D. below for further details on implementing device modifications that may or may not require a new marketing submission in accordance with 21 CFR 807.81(a)(3) and 21 CFR 814.39(a).

Contains Nonbinding Recommendations

Draft – Not for Implementation

311 A PCCP should consist of a detailed Description of Modifications, a Modification Protocol, and
312 an Impact Assessment (see Sections VI. – VIII.) because these components are intended to
313 provide FDA with the information needed for our review of the proposed modifications. The
314 detailed Description of Modifications should outline the modifications that will be made to the
315 ML-DSF, and the Modification Protocol should describe the verification and validation activities
316 (including pre-defined acceptance criteria) that will support those modifications. The Impact
317 Assessment helps to tie the Description of Modifications to the Modification Protocol in that the
318 Impact Assessment identifies the benefits and risks introduced by the specified, planned
319 modifications and how the verification and validation activities of the Modification Protocol will
320 continue to assure the safety and effectiveness of the device. The detailed Description of
321 Modifications, Modification Protocol, and Impact Assessment are all components of a PCCP and
322 should exist in tandem.
323

B. Establishing a PCCP

324
325 Premarket authorization for an ML-DSF with a PCCP must be established through the 510(k)
326 pathway, De Novo pathway, or PMA pathway, as appropriate, as a PCCP must be reviewed and
327 established as part of a marketing authorization for a device prior to a manufacturer
328 implementing any modifications under that PCCP.⁴⁵ For 510(k) submissions, in making a
329 determination of substantial equivalence where the predicate device was authorized with a
330 PCCP, the subject device must be compared to the version of the predicate device cleared or
331 approved prior to changes made under the PCCP.⁴⁶
332

333 For a manufacturer who would like to establish a new PCCP for a previously authorized device
334 with a PCCP, the marketing submission must include the appropriate marketing submission
335 requirements⁴⁷ and the proposed PCCP for the device (see Section V.E.).⁴⁸ FDA intends to focus
336 its review on the aspects of the device that are most significantly modified.⁴⁹ For example, if the
337 device has been relatively unchanged since FDA’s prior authorization and a new PCCP is
338 proposed, FDA would focus its review on the proposed PCCP.
339

340 An authorized PCCP is a technological characteristic of the authorized device with which it was
341 established. If the authorized device is significantly modified other than as specified in the
342 authorized PCCP, a new marketing submission is required for the significantly modified
343 device.⁵⁰ In that case, for the original authorized PCCP to apply to the significantly modified
344 device, the PCCP will need to be reviewed and established as part of such marketing submission.
345

⁴⁵ See sections 513(f)(2) and 515C of the FD&C Act.

⁴⁶ See section 515C(c) of the FD&C Act.

⁴⁷ See, e.g., 21 CFR 807.87, 21 CFR 860.220, or 21 CFR 814.20.

⁴⁸ E.g., through a Traditional 510(k) for a device that has already been authorized, or a PMA supplement, such as a panel-track supplement or 180-day supplement.

⁴⁹ Note that “focus of the review” is not intended to imply a review of the PCCP *only*; rather, the focus on the PCCP is as a significant change to the device that could affect the safety or effectiveness of the device.

⁵⁰ 21 CFR 807.81(a)(3) and 21 CFR 814.39(a).

Contains Nonbinding Recommendations

Draft – Not for Implementation

346 FDA encourages manufacturers to leverage the Q-Submission process for obtaining FDA
347 feedback on a proposed PCCP prior to submitting a marketing submission. For more information
348 on the Q-Submission process, refer to the [Requests for Feedback and Meetings for Medical](#)
349 [Device Submissions: The Q-Submission Program](#) guidance.⁵¹ While manufacturers are
350 encouraged to discuss their plans through a Pre-Submission, PCCPs are not authorized in Pre-
351 Submissions.
352

C. Identifying a PCCP in a Marketing Submission

353
354 The PCCP should be included as a standalone section within the marketing submission.
355 Additionally, it should be prominently included and discussed in the cover letter and included in
356 the marketing submission’s table of contents as “Predetermined Change Control Plan.” The
357 PCCP should be discussed in the marketing submission as part of the device description,
358 labeling, and relevant sections used for determining substantial equivalence or reasonable
359 assurance of safety and effectiveness. Any information pertaining to the PCCP content included
360 outside of the PCCP section should be referenced within the PCCP section.
361

362 Device labeling must comply with applicable statutes and regulations,⁵² which includes adequate
363 directions for use.⁵³ FDA may require that a change control plan include labeling required for
364 safe and effective use of the device as such device changes pursuant to such plan.⁵⁴ For ML-
365 DSFs with an authorized PCCP, the labeling should explain that the device incorporates machine
366 learning and has a PCCP so that users are aware that the device may require the user to perform
367 software updates, and that such software updates may modify the device’s performance, inputs,
368 or use. Information on the ML-DSF and its PCCP in the labeling is important in order for a user
369 to use the device safely and for the purposes for which it is intended. In particular, this
370 information may be necessary for a user to understand changes in the device and to continue to
371 use the device safely and effectively across relevant populations as the device changes pursuant
372 to the PCCP.
373

⁵¹ Available at <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/requests-feedback-and-meetings-medical-device-submissions-q-submission-program>.

⁵² 21 CFR 801 (Labeling) and 21 CFR 809 (In Vitro Diagnostic Products for Human Use). See, e.g., 21 CFR 801.5 (requiring that labeling include adequate directions for use); 21 CFR 801.109(c) (for prescription devices, requiring that labeling include any relevant hazards, contraindications, side effects, and precautions under which practitioners licensed by law to administer the device can use the device safely and for the purpose for which it is intended); and 21 CFR 809.10(b)(6) (for in vitro diagnostic products, requiring labeling accompanying any instruments use or function, installation procedures, performance characteristics and specifications, service and maintenance information, etc.).

⁵³ 21 CFR 801.5 (requiring that labeling include adequate directions for use).

⁵⁴ See sections 515C(a)(3), 515C(b)(3), and 513(f)(2) of the FD&C Act.

Contains Nonbinding Recommendations

Draft – Not for Implementation

374 The PCCP should be described in the 510(k) summary,^{55,56} De Novo decision summary,⁵⁷ or
375 PMA summary of safety and effectiveness document (SSED) and approval order.⁵⁸ Details of the
376 PCCP should be included in sufficient detail in the public-facing documents to support
377 transparency to users of FDA’s determination of substantial equivalence or reasonable assurance
378 of safety and effectiveness for the device and its range of FDA-authorized specifications.
379

380 **D. Utilizing an Authorized PCCP to Implement Device** 381 **Modifications**

382 Once a PCCP has been reviewed and established through a marketing submission, the PCCP is
383 considered part of the marketing authorization. In general, a PCCP should be evaluated within
384 the existing risk management framework of the device and implemented in accordance with the
385 manufacturer’s quality system.

386
387 Figure 1 depicts the process for implementing a modification to a device with an authorized
388 PCCP. Manufacturers should first consider whether the modification is or is not consistent with
389 the authorized PCCP; a modification is considered consistent with the authorized PCCP when
390 the modification has been specified in the Description of Modifications included in the PCCP
391 *and* has been implemented in accordance with the Modification Protocol. If the modification is
392 consistent with the authorized PCCP, a new marketing submission is not necessary, the
393 modification can be implemented in accordance with the Modification Protocol, and the
394 manufacturer should document that modification and the analysis in accordance with the
395 manufacturer’s quality system.⁵⁹

396
397 As described previously, an authorized PCCP specifies planned modifications that, if not
398 included in a PCCP, would otherwise require a new marketing submission pursuant to 21 CFR
399 807.81(a)(3) and 21 CFR 814.39(a), and in accordance with the device modifications guidances.
400 Therefore, if the modification is not consistent with the authorized PCCP – including if the
401 specific modification is not included in the authorized PCCP or if the modification is included in

⁵⁵ In accordance with 21 CFR 807.92, “a 510(k) summary shall be in sufficient detail to provide an understanding of the basis for a determination of substantial equivalence.” This includes, but is not limited to, a description of the device, and for those 510(k) submissions in which a determination of substantial equivalence is also based on an assessment of performance data, non-clinical tests, and clinical tests.

⁵⁶ If a sponsor chooses to submit a 510(k) Statement rather than 510(k) Summary, the sponsor should provide to requestors all PCCP information in the 510(k) that supports transparency to users of FDA’s determination of substantial equivalence for the device and its range of FDA-authorized specifications, as such information constitutes safety and effectiveness information. See 21 CFR 807.93 for requirements on the content and format of a 510(k) Statement.

⁵⁷ The De Novo decision summary is intended to present an objective and balanced summary of the scientific evidence that served as the basis for the FDA’s decision to grant a De Novo request; see <https://www.fda.gov/medical-devices/premarket-submissions/de-novo-classification-request>.

⁵⁸ In accordance with 21 CFR 814.9(e), “FDA will make available to the public ... a detailed summary of information submitted to FDA respecting the safety and effectiveness of the device that is the subject of the PMA and that is the basis for the order.”

⁵⁹ Manufacturers are required to comply with the quality system regulation (21 CFR 820). The device and PCCP must be implemented consistent with 21 CFR 820, including, but not limited to: 21 CFR 820.30 Design controls; 21 CFR 820.90 Nonconforming products; and 21 CFR 820.100 Corrective and preventive action.

Contains Nonbinding Recommendations

Draft – Not for Implementation

402 the authorized PCCP but is not implemented in accordance with the methods and specifications
403 described in the Modification Protocol – the manufacturer should then proceed to evaluate the
404 modification in accordance with applicable laws and regulations and the device modifications
405 guidances, if applicable, and proceed accordingly. If, after review of applicable laws and
406 regulations, a new marketing submission is required,⁶⁰ then the manufacturer must submit the
407 appropriate marketing submission before the modified device is marketed. The appropriate
408 marketing submission could request authorization for 1) a device modification effected through a
409 change to the authorized PCCP⁶¹ (see Section V.E.); or 2) a device modification not
410 implemented through a PCCP; or 3) both. In each of these cases, a marketing submission for the
411 device modification must include the appropriate marketing submission requirements⁶² for the
412 device. As noted in Section V.B., an authorized PCCP is a technological characteristic of its
413 authorized device with which it was established. Therefore, for the original authorized PCCP to
414 apply to the modified device, the manufacturer must include the proposed PCCP in the
415 marketing submission for the device modification;⁶³ the PCCP is reviewed and established as
416 part of the review of the modified device.

417
418 See [Appendix B](#) for example scenarios for implementing modifications to a device with an
419 authorized PCCP. Manufacturers may contact the appropriate FDA review division (e.g., through
420 a Pre-Submission)⁶⁴ for a discussion about the proposed modification and whether it may be
421 considered consistent with the current, authorized PCCP.
422

⁶⁰ See, e.g., 21 CFR 807.81(a)(3) and 21 CFR 814.39(a).

⁶¹ A change to the authorized PCCP could include a change in Description of Modifications, the Modification Protocol, and/or the Impact Assessment, as appropriate.


⁶² See, e.g., 21 CFR 807.87, 21 CFR 860.220, or 21 CFR 814.20.

⁶³ See sections 513(f)(2) and 515C of the FD&C Act.

⁶⁴ See FDA's guidance "Requests for Feedback and Meetings for Medical Device Submissions: The Q-Submission Program" available at <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/requests-feedback-and-meetings-medical-device-submissions-q-submission-program>."

Contains Nonbinding Recommendations

Draft – Not for Implementation



*For the modified device to have a PCCP, a PCCP should be submitted with the marketing submission so that the device and PCCP can be authorized together.

423
424
425
426

Figure 1: Implementing a Modification to a Device with an Authorized PCCP

427

E. Modifying a PCCP for an Authorized Device

428 Because the modifications described in the PCCP include device changes that would otherwise
429 require a PMA supplement, De Novo submission, or new 510(k) premarket notification, at this
430 time, FDA believes that modifications to an authorized PCCP will generally constitute changes
431 to the ML-DSF that require a new marketing submission for the device, which will include the
432 modified PCCP.⁶⁵ In other words, FDA expects that the modified PCCP will need to be reviewed
433 and established as part of the premarket review of the modified device because a modification to
434 the PCCP will generally significantly affect the safety or effectiveness of the device.⁶⁶ In those
435 cases where modifications to the PCCP are the only significant modifications introduced since
436 FDA's prior authorization for the device and its PCCP, FDA intends to focus its review on the
437 proposed PCCP. For a manufacturer who would like to modify a PCCP for a previously
438 authorized device with a PCCP, the marketing submission must include the appropriate
439 marketing submission requirements for the device and the proposed PCCP.⁶⁷
440

⁶⁵ Section 510(l)(1) and section 515(d)(5)(A)(i) of the FD&C Act.

⁶⁶ See, e.g., 21 CFR 807.87, 21 CFR 860.220, or 21 CFR 814.20.

⁶⁷ See sections 513(f)(2) and 515C of the FD&C Act.

441 **VI. Description of Modifications**

442 As introduced above, a description of each planned modification to an ML-DSF should be
443 included in the Description of Modifications section of a PCCP. The detailed description should
444 describe changes to the device characteristics and performance resulting from implementation of
445 the modifications. To ensure an efficient review, FDA recommends that a PCCP include only a
446 limited number of modifications that are specific, and that can be verified and validated.
447

448 **A. Goals of the Description of Modifications Section**

449 A dedicated Description of Modifications section in a PCCP identifies the specific, planned
450 modifications to the ML-DSF that the manufacturer intends to implement. The Description of
451 Modifications draws a “range of FDA-authorized specifications” around the initial characteristics
452 and performance of the device that, following the agreed upon verification and validation
453 described in the Modification Protocol, can be implemented without a new marketing
454 submission. Upon FDA review of a PCCP, it is possible that FDA may determine that a
455 Modification Protocol supports some but not all modifications identified in a PCCP; in such
456 cases, only those modifications that are appropriate in the FDA’s findings of substantial
457 equivalence or reasonable assurance of safety and effectiveness would be included in the
458 authorized PCCP.
459

460 **B. Content of the Description of Modifications Section**

461 The Description of Modifications should enumerate the list of individual proposed device
462 modifications discussed in the PCCP, as well as the specific rationale for the change to each part
463 of the ML-DSF that is planned to be modified. In some situations, a Description of Modifications
464 will consist of multiple modifications. It may be helpful to reference the labeling changes that are
465 associated with each modification in the Description of Modifications section (such labeling
466 changes should be included in a Modification Protocol, as described in Section VII.B.).
467

468 FDA recommends that a PCCP include modifications that are specific, and that can be verified
469 and validated. Modifications should also be presented at a level of detail that permits
470 understanding of the specific modifications that will be made to the ML-DSF. Each modification
471 should be linked to a specific performance evaluation activity within the Modification Protocol
472 (for an example, see Table 1 in Section VII.C.).
473

474 The Description of Modifications should clearly state if the planned modifications are proposed
475 to be implemented automatically (i.e., whether the modifications are implemented automatically
476 by software) or whether modifications are implemented manually (i.e., involving steps that
477 require human input, action, review, and/or decision-making, and therefore are not implemented
478 automatically). Understanding that this is an evolving area, FDA is proposing to consider PCCPs
479 for ML-DSFs where modifications are implemented automatically to the extent the Agency can
480 properly review them for substantial equivalence to the predicate or a reasonable assurance of
481 safety and effectiveness. The Agency recognizes that this subset of ML-DSFs has an additional
482 degree of complexity; as with all ML-DSFs, FDA will consider the benefit-risk assessment, and

Contains Nonbinding Recommendations

Draft – Not for Implementation

483 the Agency’s current experience applying this policy when reviewing PCCPs containing
484 automatically implemented modifications.

485
486 The Description of Modifications should also clearly specify if the proposed modifications will
487 be implemented in a uniform manner across all devices on the market (sometimes referred to as
488 homogenous or global changes, or global adaptations) or implemented differently on different
489 devices on the market based on, for example, the unique characteristics of a specific clinical site
490 or individual patients (sometimes referred to as heterogenous or local changes, or local
491 adaptations). For local adaptations, the Description of Modifications should include describing
492 what local factors or conditions warrant a local change.

493

494 **C. Types of Modifications**

495 Modifications that are appropriate for a PCCP include those that are intended to maintain or
496 improve the safety or effectiveness of the device. Modifications proposed within the Description
497 of Modifications should be able to be verified and validated within the existing quality system of
498 the device. As such, not all modifications may be appropriate for inclusion within a PCCP. Types
499 of modifications that may be acceptable within a PCCP include:

500

- 501 (i) modifications related to quantitative measures of ML-DSF performance specifications;
- 502 (ii) modifications related to device inputs to the ML-DSF; and
- 503 (iii) limited modifications related to the device’s use and performance (e.g., for use
504 within a specific subpopulation).

505

506 Examples of modifications related to quantitative measures of ML-DSF performance
507 specifications include improvements to analytical and clinical performance resulting from re-
508 training the ML model based on new data within the intended use population from the same type
509 and range of input signal.

510

511 Modifications related to device inputs to the ML-DSF may involve expanding the algorithm to
512 include new sources of the same signal type (e.g., different makes, models, or versions of a data
513 acquisition system) or limited modifications related to new types of inputs.

514

515 Modifications related to the device’s use and performance could include authorization of a
516 device for a specific subset of a population within the originally indicated population based on
517 re-training on a larger data set for that subpopulation that was not previously available.

518

519 All modifications included in a PCCP must maintain the device within the device’s intended
520 use.⁶⁸ At this time, FDA expects that modifications included in a PCCP should also maintain the
521 device within the device’s indications for use.⁶⁹ As with modifications to the intended use, FDA

⁶⁸ Section 515C(a)(2) and section 515C(b)(2) FD&C Act.

⁶⁹ FDA has a long-standing policy of applying the definition of indications for use in the PMA regulation at 21 CFR 814.20(b)(3)(i) in the same way in the 510(k) context. See the FDA guidance “The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)],” available at <https://www.fda.gov/regulatory->

Contains Nonbinding Recommendations

Draft – Not for Implementation

522 believes modifications to the indications for use would not allow the device to remain safe and
523 effective.⁷⁰

524
525 Recognizing there is a spectrum of risk for devices, for the purposes of reviewing a PCCP, FDA
526 intends to, among other considerations, take into account the benefit-risk profile of the specific
527 device that is the subject of the PCCP, the specific modifications being proposed, and its
528 experience applying this policy across different device types. See [Appendix B](#) for examples of
529 modifications.
530

531 **VII. Modification Protocol**

532 The Modification Protocol includes the documentation describing the methods that will be
533 followed when developing, validating, and implementing modifications delineated in the
534 Description of Modifications section of the PCCP. The Modification Protocol includes the
535 verification and validation activities (including pre-defined acceptance criteria) for those
536 modifications and is intended to provide a step-by-step delineation of how the modifications
537 proposed in the PCCP will be implemented while assuring the device remains safe and effective.
538 Documentation of modifications verified and validated per the Modification Protocol must be
539 compliant with the quality system (QS) regulation.⁷¹ The QS regulation requires manufacturers
540 of finished medical devices to review and approve modifications to device design and production
541 (21 CFR 820.30 and 820.70) and document changes and approvals in the device master record
542 (21 CFR 820.181).
543

544 **A. Goals of the Modification Protocol Section**

545 Whereas the Description of Modifications outlines the planned modifications to an ML-DSF, the
546 Modification Protocol describes the methods that will be followed when developing, validating,
547 and implementing those modifications, to ensure the device remains safe and effective. The
548 methods described in the Modification Protocol should be consistent with and support the
549 modifications outlined in the Description of Modifications.
550

551 The goals of the Modification Protocol are to:

- 552
- 553 • Identify the methods and data used to develop, validate, and implement all proposed
554 modifications;
 - 555 • Identify the test methods, data, statistical analyses, and specified acceptance criteria
556 for all proposed modifications;
 - 557 • Ensure that the information that would otherwise be generated and submitted to the
558 Agency (i.e., if the modifications were implemented on a device that did not have an
559 authorized PCCP) will be generated by the manufacturer for each modification and

[information/search-fda-guidance-documents/510k-program-evaluating-substantial-equivalence-premarket-notifications-510k.](#)

⁷⁰ Section 515C(a)(2)(A) and section 515C(b)(2) FD&C Act.

⁷¹ 21 CFR Part 820.

Contains Nonbinding Recommendations

Draft – Not for Implementation

- 560 maintained consistent with recordkeeping requirements⁷² and in accordance with the
561 manufacturer's QS;
- 562 • Ensure that the risks that have been identified in the Impact Assessment as related to
563 modifications detailed in the Description of Modifications (including the update
564 process and communication to users) will be mitigated; and
 - 565 • Be least burdensome for the manufacturer to develop and for FDA to review. This
566 includes being traceable and specific to the modifications detailed in the Description
567 of Modifications section and sufficiently comprehensive to support specific
568 modifications.
- 569

570 This draft guidance identifies four primary components of a Modification Protocol, described
571 below, that outline a manufacturer's 1) data management practices, 2) re-training practices, 3)
572 performance evaluation protocols, and 4) update procedures, including communication and
573 transparency to users and real-world monitoring plans, for each modification in a PCCP. In
574 FDA's experience, these four components generally provide FDA with the information needed to
575 evaluate the PCCP. For a particular marketing submission, additional components of a
576 Modification Protocol may be important to provide a reasonable assurance of safety and
577 effectiveness.

578

579 In some cases, the same methods in each component of the Modification Protocol may support
580 all modifications in a PCCP for a device. In other cases, the same methods in each component
581 may not be adequate for every modification in a PCCP. It is important to note, however, that for
582 each planned modification provided in the Description of Modifications, FDA recommends that
583 each of the four primary components of a Modification Protocol be addressed. Additionally, the
584 Modification Protocol should include a description of how its proposed methods are similar to or
585 different from methods used elsewhere in the marketing submission. For example, if the
586 validation methods in the Modification Protocol represent a subset of the original testing for the
587 device, or if the acceptance criteria for the validation are different, manufacturers should
588 describe these differences and provide a justification. The justification for a different
589 methodology may include references to other marketing submissions where the methodology
590 was used for similar modifications.

591

592 As noted above in Section V.E., manufacturers should follow their risk management processes to
593 develop a Modification Protocol that considers each modification. Upon FDA review of a PCCP,
594 FDA may determine that the Modification Protocol supports some but not all proposed
595 modifications identified in the PCCP. In such cases, only those modifications that were
596 supportable by the proposed Modification Protocol would be appropriate for inclusion in the
597 PCCP and would become part of the authorized PCCP. Those modifications that were not
598 supportable by the proposed Modification Protocol, or that FDA considered inappropriate for
599 other reasons (e.g., the modification changes the device's indications for use), would be removed
600 from the PCCP.

601

⁷² 21 CFR 820 Subpart M – Records.

602 **B. Content of the Modification Protocol Section**

603 As part of their Modification Protocol, manufacturers should outline the methods for each
604 component described below. Example elements of each of the four Modification Protocol
605 components are provided in [Appendix A](#).
606

607 **(1) Data management practices**

608 *What they are:* ML-DSF training and testing typically utilize data that include the inputs (e.g.,
609 medical images) that will be used by the device and often utilize a label or ‘reference standard’
610 that is determined through a reference standard determination and/or an annotation process.
611 Training data and testing data are sequestered to prevent overfitting and misquotes of test
612 performance. The training and testing methods aim to identify and eliminate bias in the data
613 (which may be inherent from historical datasets) and to improve the robustness and resilience of
614 these algorithms to withstand changing clinical inputs and conditions. To support modifications
615 to an ML-DSF that may need training and/or testing, it is anticipated that new data (i.e., data that
616 were not used to develop the initial ML-DSF) will be collected. The data management practices
617 in a Modification Protocol should outline how those new data will be collected, annotated,
618 curated, stored, retained,⁷³ controlled, and used by the manufacturer for each modification. The
619 data management practices in a Modification Protocol should also clarify the relationship
620 between the Modification Protocol data and the data used to train and test the initial and
621 subsequent versions of the ML-DSF. It should also describe the control methods employed to
622 curb the potential for data or performance information leaking into the development process
623 during modification development or assessment.
624

625 *Why they are recommended:* This information allows FDA to understand the manufacturer’s data
626 management practices that will be used to support each modification to an ML-DSF, including 1)
627 how the manufacturer plans to obtain and use training and testing data that are complete and
628 representative of the proposed intended use populations (e.g., with respect to race, ethnicity,
629 disease severity, gender, age, etc.⁷⁴); 2) whether identifiable subpopulations will be adequately
630 represented, including intersectional groups, and separated into training and testing sets to
631 minimize ML model bias; 3) how training and testing data will be sequestered to prevent
632 overfitting and misquotes of test performance; 4) how older data will be complemented or
633 replaced by newer data so that the performance is representative of the current patient population
634 and standard of care; 5) whether the reference standard represents the best available process for
635 determining the ground truth; and 6) how the data management practices may reduce the
636 potential to produce discriminatory outcomes. A clear explanation of data management practices
637 also provides assurance to FDA that modifications to the ML-DSF are based on data that are

⁷³ The QS regulation requires manufacturers to retain all records for a period of time equivalent to the design and expected life of the device, but in no case less than 2 years from the date of release for commercial distribution by the manufacturer (21 CFR 820.180(b)).

⁷⁴ We recommend that manufacturers consider additional characteristics, such as those described in the Blueprint for an AI Bill of Rights (<https://www.whitehouse.gov/ostp/ai-bill-of-rights/>): race, color, ethnicity, sex (including pregnancy, childbirth, and related medical conditions, gender identity, intersex status, and sexual orientation), religion, age, national origin, disability, veteran status, and genetic information.

Contains Nonbinding Recommendations

Draft – Not for Implementation

638 representative of the device indications for use. This includes information regarding products
639 that will be used to generate data as inputs for the ML-DSF, patient populations in which the
640 device will be used, and clinical scenarios where the device will be used.

641
642 *What manufacturers should include in a submission:* Examples of the types of information
643 manufacturers should provide in a Modification Protocol describing their data management
644 practices are provided in [Appendix A](#). In general, this information should describe: how data will
645 be collected, including clinical study protocols with inclusion/exclusion criteria; information on
646 how data will be processed, stored, and retained;⁷⁵ the process that will be followed to determine
647 the reference standard; the quality assurance process related to the data; the data sequestration
648 strategies that will be followed during data collection to separate the data into training and
649 testing sets; and the protocols in place to prevent access during the training and tuning process to
650 data intended for performance testing.

651

652 **(2) Re-training practices**

653 *What they are:* ML software generally involves multiple processing steps from the point the ML-
654 DSF receives the input data to the point it provides an output. The re-training practices
655 component of a Modification Protocol should identify the processing steps that are subject to
656 change for each modification and the methods that will be used by the manufacturer to
657 implement modifications to the ML-DSF. In addition, if re-training involves ML architecture
658 modifications (e.g., in a neural network, modifications to training hyperparameters or the number
659 of nodes, layers, etc.), the re-training practices component of a Modification Protocol should also
660 describe the rationale or the justification for each specific architecture modification.

661
662 *Why they are recommended:* Information on the manufacturer’s re-training practices allows FDA
663 to understand how the proposed modifications will be achieved through re-training, to determine
664 if modifications are implemented following appropriate, well-defined practices,⁷⁶ and to
665 determine if the performance evaluation and update procedures (discussed below) support the
666 modifications. Information on the manufacturer’s re-training practices is typically provided in
667 the “device description” of a marketing submission for the majority of ML-DSFs that FDA
668 reviews. The specifics of what should be included in this component of the Modification
669 Protocol will depend on the type of modification and specific device.

670

671 *What manufacturers should include in a submission:* Examples of the types of information
672 manufacturers should provide in a Modification Protocol describing their re-training practices
673 are provided in [Appendix A](#). In general, this information should identify the objective of the re-
674 training process, provide a description of the ML model, identify the device components that
675 may be modified, outline the practices that will be followed (e.g., data sequestration strategies
676 during re-training), and identify any triggers for re-training (e.g., when new data reaches a
677 certain size or when a drift in data is observed over time).

⁷⁵ See 21 CFR 820.180(b).

⁷⁶ For example, FDA has published a document on “Good Machine Learning Practice for Medical Device Development: Guiding Principles,” available at <https://www.fda.gov/medical-devices/software-medical-device-samd/good-machine-learning-practice-medical-device-development-guiding-principles>.

Contains Nonbinding Recommendations

Draft – Not for Implementation

678

679

(3) Performance evaluation

680 *What they are:* The FDA may require that performance requirements for changes made under the
681 plan be provided in a PCCP.⁷⁷ Performance evaluation methods should describe the processes
682 that will be followed to validate that the modified ML-DSF will meet the specifications
683 identified as part of a specific modification, in addition to maintaining the specifications that are
684 not part of the modification but may be impacted by the modification. Performance evaluation
685 should include the plans for verification and validation of the entire device following ML-DSF
686 modifications for each individual modification and in aggregate for all implemented
687 modifications. This includes, but is not limited to, ML model testing protocols comparing the
688 newly modified device to both the original device (the version of the device without any
689 modifications implemented) and the last modified version of the device. For example, for device
690 software functions that drive hardware functionality, performance evaluation should include not
691 only the device software functions, but also the effect of the modifications on hardware
692 functionality. The content of this section in a Modification Protocol should provide details on the
693 study design, performance metrics, pre-defined acceptance criteria, and statistical tests for each
694 planned modification. More comprehensive testing can potentially support a broader set of
695 proposed modifications.

696

697 *Why they are recommended:* Information regarding the manufacturer's performance evaluation
698 methods allow FDA to confirm that appropriate study designs, including performance metrics
699 and statistical tests, will be used to evaluate the effect of modifications on overall device
700 performance. Performance evaluation of the device is essential to ensure that specified
701 acceptance criteria for all proposed modifications will continue to be met over the range of FDA-
702 authorized specifications.

703

704 *What manufacturers should include in a submission:* Examples of the types of information
705 manufacturers should provide in a Modification Protocol describing their performance evaluation
706 are provided in [Appendix A](#). In general, this information should describe how performance
707 evaluation will be triggered; how sequestered test data representative of the clinical population
708 and intended use will be applied for testing; what performance metrics will be computed; and
709 what statistical analysis plans will be employed to test hypotheses relevant to performance
710 objectives for each modification. In addition, the Modification Protocol should affirmatively
711 state that if there is a failure in performance evaluation for a specific modification, the failure(s)
712 will be recorded, and the modification will not be implemented.

713

714

(4) Update procedures

715 *What they are:* Data management practices, re-training practices, and performance evaluation
716 described above largely relate to making and testing modifications to the ML-DSF. Once these
717 meet the performance objectives, manufacturers will need to update the ML-DSF to implement
718 the modifications and communicate information to users about the modifications that is needed

⁷⁷ Section 515C(a)(3) and (b)(3) of the FD&C Act.

Contains Nonbinding Recommendations

Draft – Not for Implementation

719 to safely use the device. The update procedures in a Modification Protocol should describe how
720 manufacturers will update their devices to implement the modifications, provide appropriate
721 transparency to users, and, if appropriate, updated user training about the modifications and
722 perform real-world monitoring, including notification requirements if the device does not
723 function as intended pursuant to the authorized PCCP.⁷⁸ The PCCP should include a description
724 of any labeling changes that will result from the implementation of the modifications. The
725 available labeling must include adequate directions for use and reflect information about the
726 current version(s) of the ML-DSF available to the user, including information regarding site-
727 specific modifications.⁷⁹ The labeling should not reflect information on modifications to the ML-
728 DSF that have not been implemented in the available version, because it could cause confusion
729 and would be misleading. If such information is included in the labeling, the ML-DSF could be
730 deemed misbranded.⁸⁰

731
732 *Why they are recommended:* Information on the manufacturer's update procedures allows FDA
733 to understand 1) how risks from implementing modifications may be mitigated by the update
734 process; 2) how communication regarding the device updates will be provided to users (e.g., so
735 that updates in device output results will be correctly interpreted by users); 3) how the device
736 operation will remain reliable after the update; and 4) how all stakeholders will be kept up-to-
737 date about device functionality and performance. In addition, it is important for FDA to
738 understand how potential risks associated with the update process, itself, may be mitigated.

739
740 *What manufacturers should include in a submission:* Examples of the types of information
741 manufacturers should provide in a Modification Protocol describing their update procedures are
742 provided in [Appendix A](#). In general, this information should include 1) confirmation that the
743 verification and validation plans for the modified version of the device are the same as those that
744 have been performed for the version of the device prior to the implementation of the
745 modifications, or identification of any differences between the two plans; 2) a description of how
746 software updates will be implemented; 3) a description of how legacy users will be affected by
747 the software update (if applicable); and 4) a description of how modifications will be
748 communicated to the users, including transparency on any differences in performance,
749 differences in performance testing methods, and/or known issues that were addressed in the
750 update (e.g., whether there is an improvement in performance in a subpopulation of patients).
751 Communication of performance changes should be consistent with performance evaluation
752 described in the Modification Protocol.

753

C. Traceability Between the Description of Modifications Section and the Modification Protocol Section

755

⁷⁸ Section 515C(a)(3) and (b)(3) of the FD&C Act.

⁷⁹ See 21 CFR 801.5, requiring that labeling include adequate directions for use including statements of all conditions, purposes, or uses for which the device is intended.

⁸⁰ See section 502(a)(1) of the FD&C Act, stating that a medical device is deemed misbranded if its labeling is false or misleading in any particular.

Contains Nonbinding Recommendations

Draft – Not for Implementation

756 The PCCP should clearly delineate which parts of the Modification Protocol are applicable to
757 each modification within the Description of Modifications. For a PCCP with multiple
758 modifications, this may be accomplished through a traceability table; a sample traceability table
759 is provided below in Table 1. This sample traceability table provides an example of how a
760 manufacturer can depict the traceability between the Description of Modifications and
761 Modification Protocol, as well as how to provide clear references to where within the PCCP this
762 information is located in a marketing submission.

763
764 **Table 1. Example of Description of Modifications to Modification Protocol Traceability**
765 **Table**

766
767 Table 1: A traceability table can help to identify where each method supporting each modification may be found in the marketing
768 submission.

	Modification Protocol Component			
Modification	Data management practices	Re-training practices	Performance evaluation	Update procedures
<i>Modification #1</i>	<i>Method A (see Section X.A)</i>	<i>Method D (see Section X.D)</i>	<i>Method G (see Section X.G)</i>	<i>Method J (see Section X.J)</i>
<i>Modification #2</i>	<i>Method A (see Section X.A)</i>	<i>Method E (see Section X.E)</i>	<i>Method H (see Section X.H)</i>	<i>Method J (see Section X.J)</i>
<i>Modification #3</i>	<i>Method B (see Section X.B)</i>	<i>Method F (see Section X.F)</i>	<i>Method I (see Section X.I)</i>	<i>Method J (see Section X.J)</i>

769

770 **VIII. Impact Assessment**

771 An Impact Assessment, in the context of a PCCP, is the documentation of the assessment of the
772 benefits and risks of implementing a PCCP for an ML-DSF, as well as the mitigations of those
773 risks. The manufacturer’s existing quality system should be used as the framework in which to
774 conduct an Impact Assessment for the modifications set forth in the PCCP.

775
776 Documentation for an Impact Assessment provided to the Agency in a marketing submission
777 containing a PCCP should 1) compare the version of the device with each modification
778 implemented to the version of the device without any modifications implemented, 2) discuss the
779 benefits and risks, including risks of social harm, of each individual modification, and 3) discuss
780 how the activities proposed within the Modification Protocol continue to reasonably ensure the
781 safety and effectiveness of the device. The Impact Assessment documentation in a marketing
782 submission should also discuss 4) how the implementation of one modification impacts the
783 implementation of another, and 5) the collective impact of implementing all modifications. FDA

Contains Nonbinding Recommendations

Draft – Not for Implementation

784 believes it is important to address these elements in an Impact Assessment in order to
785 demonstrate that the combination of the proposed modifications is unlikely to introduce
786 additional, unmitigated risks, and that the safety and effectiveness of the device under review is
787 maintained as modifications are implemented.

788
789 Impact Assessment documentation in a marketing submission should discuss how the individual
790 modifications included in the PCCP impact not only the ML-DSF, but also how they impact the
791 overall functionality of the device, including how they impact other device software functions, as
792 well as device hardware. Additionally, if the ML-DSF is a device function of a multiple function
793 device product, we recommend considering FDA’s guidance [Multiple Function Device Products:
794 Policy and Considerations](#)⁸¹ to determine if any information should be included in the Impact
795 Assessment documentation in a marketing submission (and the marketing submission overall) so
796 that FDA may assess the impact of the “other function(s)” on the safety or effectiveness of the
797 ML-DSF and modifications to the ML-DSF.

798
799 The Agency acknowledges that for some devices, it may be least burdensome to include the
800 content of the Impact Assessment within the Modification Protocol rather than as a separate
801 section within the PCCP.

⁸¹ See FDA’s guidance “Multiple Function Device Products: Policy and Considerations” available at <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/multiple-function-device-products-policy-and-considerations>.

802 **Appendix A: Example Elements of Modification Protocol** 803 **Components for ML-DSFs**

804 In general, a Modification Protocol that is included as part of a PCCP in a marketing submission
805 should include four components that outline a manufacturer’s 1) data management practices, 2)
806 re-training practices, 3) performance evaluation protocols, and 4) update procedures, for each
807 modification in the Description of Modifications for the ML-DSF. However, manufacturers may
808 include other or additional components if they believe that their proposed protocols do not fit
809 into any of these four components. Examples of questions for consideration and the types of
810 information manufacturers should provide in these components of a Modification Protocol are
811 provided below.

812
813 Note that this is a developing area, and as FDA gains experience, these example questions may
814 change. *The items below are also not an exhaustive list of topics that a manufacturer is expected*
815 *to cover, and all questions may not apply to all marketing submissions.* Likewise, the Agency
816 may request additional Modification Protocol components or information to be included in a
817 PCCP for some device types so that the Agency can review the PCCP as part of the marketing
818 submission.⁸² Some sections of a Modification Protocol may be more or less detailed depending
819 on the complexity and risks of each modification in the PCCP.

820

821 **(1) Data Management**

822 Different data can be collected and used for training and testing ML model updates. For
823 collection of new training and testing data, the Modification Protocol should include how the
824 data will be used (e.g., for ML model development or testing), and how the data management
825 supports these uses.

826 **a. Collection protocols**

- 827 1.a.1. For each modification, what are the inclusion/exclusion criteria for data
828 collection, and how are they linked to the intended use population?
- 829 1.a.2. What is the intended distribution of your data set along covariates describing the
830 patient population (e.g., sex, age, race, height, weight, disease conditions) and
831 data acquisition conditions (e.g., sites, data acquisition devices/methods, imaging
832 and reconstruction protocols)? Is this distribution representative of the intended
833 use population, including intersectional groups?
- 834 1.a.3. Will the data be collected prospectively or retrospectively? Will the data set
835 include consecutive cases within a given date range? Otherwise, if random
836 sampling is planned, what method or technique will be used and how will it
837 account for bias and randomness?
- 838 1.a.4. Are there any plans for enrichment or stratified sampling to include specific
839 patient subgroups (e.g., sex, age, race)?

⁸² Such information would be required in the marketing submission pursuant to 21 CFR 807.81(a)(3) and 21 CFR 814.39(a).

Contains Nonbinding Recommendations

Draft – Not for Implementation

- 840 1.a.5. What is the number and geographical distribution of data collection sites?
841 1.a.6. What are the measures to mitigate potential unwanted bias in learning or
842 performance estimation, for example, due to issues related to new training or
843 testing data, respectively?
844 1.a.7. What are the strategies and measures to understand and mitigate potential biases
845 in the data, such as those due to historical inequalities to medical treatment access
846 by different populations?
847 1.a.8. What are the strategies to ensure data sets remain relevant over time with respect
848 to changes in, for example, data acquisition technologies or protocols, clinical
849 practice, patient populations, and disease conditions?
850 1.a.9. Are data collection, storage, retention, and use protocols in compliance with
851 regulations for human subject protections and requirements for clinical
852 investigations (e.g., pursuant to 21 CFR Part 812, 45 CFR Part 46, 21 CFR Part
853 50, and 21 CFR Part 506, as applicable)?
854 1.a.10. For ML-DSFs that use input data from dedicated acquisition systems (e.g.,
855 software device functions in a patient monitor that uses connected sensors), is the
856 data acquired with the systems and settings with which the ML-DSF will be used?
857 For device software functions that use input data from different acquisition
858 systems (e.g., interoperable medical devices), does the data acquired meet the
859 input specifications of the ML-DSF?

860 **b. Assurance of Data Quality**

- 861 1.b.1. What techniques will be employed to fortify data consistency and completeness?
862 1.b.2. What are the strategies used to promote data authenticity, transparency, and
863 integrity?
864 1.b.3. How will potentially missing data elements within a case/record be handled?
865 1.b.4. Are there criteria for including/excluding cases/records based on data quality (in
866 addition to inclusion/exclusion criteria listed in 1.a.1. above), and if so, what are
867 the criteria and rationale?
868 1.b.5. If data might be excluded as a result of the quality assurance process, what
869 methods are planned to minimize the impact on the generalizability of training
870 and accuracy of testing?
871 1.b.6. Are there strategies to trace a data issue to an individual record? What are the
872 strategies to identify and investigate data issues?
873 1.b.7. Will data that are obsolete or no longer needed be removed?
874 1.b.8. What controls are in place to prevent and identify unauthorized access or
875 manipulation of the training and testing data sets? For example, what controls are
876 in place to prevent malicious addition or deletion of data for the purpose of
877 adversarial machine learning?
878 1.b.9. Is there an automated process to ensure data quality?

879 **c. Reference standard determination**

880 For the purposes of this guidance, the reference standard is the best available truth standard to
881 define the true condition for each patient/case/record. The reference standard may be used in
882 device training, device testing, or both.

Contains Nonbinding Recommendations

Draft – Not for Implementation

- 883
884 1.c.1. What is the justification for the method for the determination of the reference
885 standard?
886 1.c.2. If the reference standard is based on evaluations from clinicians, what was the
887 grading protocol used (e.g., what are the total number of clinicians who
888 participated and their qualifications; what data are these clinicians provided with;
889 and how are the clinicians' evaluations collected/adjudicated for determining the
890 reference standard)?
891 1.c.3. What is the strategy for addressing cases where results obtained using a reference
892 standard may be equivocal or missing?
893 1.c.4. What is the uncertainty inherent in your reference standard?
894 1.c.5. Will any of the methods for determining the reference standard be automated?
895 Are there differences between the reference standards used for training versus
896 testing?
897 1.c.6. Are there differences between the reference standard used to support the initial
898 ML-DSF marketing authorization and the reference standard being applied to
899 update the ML model?

900 **d. Sequestration of test data sets**

901 For the purposes of this guidance, sequestration of test data sets means that manufacturers do not
902 have access to the test data set for the purpose of ML-DSF development.
903

- 904 1.d.1. What strategies will be employed at the outset of data collection to shield the test
905 data set from the ML-DSF development?
906 1.d.2. What are the specific procedures to be followed so that the test data set remains
907 sequestered during re-training?
908 1.d.3. If test data are planned to be used multiple times for performance evaluation, what
909 measures are in place to prevent unwanted bias from being introduced through
910 ML model manufacturers learning substantial information about the test data set
911 and results?
912

913 **(2) Re-Training**

914 **a. Re-training objectives and focus**

- 915 2.a.1. How are the modifications presented in the Description of Modifications in the
916 PCCP related to the planned re-training methods?
917 2.a.2. Which parts of the ML-DSF are planned to be modified (e.g., transfer learning,
918 data pre-processing, data augmentation, only a certain set of coefficients, ML
919 architecture and hyper-parameters, loss functions, optimization methods and
920 criteria, types of ML model inputs and outputs), and what are the details of the
921 planned modifications to the ML-DSF design? What is the specific rationale for
922 the change to each part that is planned to be modified?
923 2.a.3. For each part of the ML-DSF that will be modified, is ML model re-training
924 needed to achieve the modifications specified in the PCCP?

Contains Nonbinding Recommendations

Draft – Not for Implementation

925 2.a.4. If re-training applies to only certain parts of the ML-DSF, what are the plans to
926 ensure that other functions or software components are not affected?

927 **b. Re-training implementation:**

928 2.b.1. What are the triggers for re-training (e.g., when new data reaches a certain size,
929 when a drift is observed, periodically in time)?

930 2.b.2. What strategies will be employed to identify and limit overfitting?

931 2.b.3. Are there risks related to ML model bias introduced by re-training a modified ML
932 model, and if so, what are planned mitigations?
933

934 **(3) Performance Evaluation**

935 **a. Triggers to initiate performance evaluation**

936 3.a.1. What are the triggers for initiating performance evaluation of a re-trained ML
937 model or modified ML-DSF (e.g., re-training shows a certain performance level
938 on the training or validation data, test data reaches a certain size, periodically in
939 time)?

940 3.a.2. How frequently is this expected to occur?

941 **b. Assessment metrics and elements**

942 3.b.1. How is the Data Management Plan in (1) above applied to produce the testing
943 data for performance evaluation that are different from any training or tuning
944 data?

945 3.b.2. What metrics will be computed to understand device performance?

946 3.b.3. How do these metrics demonstrate that the modified device can be safely used?

947 3.b.4. How will the metrics provide a comprehensive assessment of device performance
948 and patient safety?

949 3.b.5. What corner cases (i.e., cases outside the norm) or known challenging scenarios
950 will be evaluated?

951 **c. Statistical analysis plans**

952 3.c.1. What is the plan for evaluating equivalent or improved performance with respect
953 to previously validated versions, including the original version, of the ML-DSF?

954 3.c.2. What are the high-risk subpopulations and subgroups (e.g., sex, gender
955 differences, acquisition protocols) that need to be evaluated?

956 3.c.3. How will this evaluation be used to support labeling specifications?

957 3.c.4. How will you test that performance in one area (e.g., sensitivity) does not result in
958 degrading performance in another (e.g., specificity)?

959 3.c.5. How will the sample size be determined?

960 3.c.6. Is the primary analysis based on the intention-to-diagnose population (no study
961 subjects will be excluded) or the per-protocol population (subjects with protocol
962 violations will be excluded)?

963 3.c.7. How is variability in the reference standard accounted for (e.g., in the case of
964 reader variability when clinical interpretation is used)? When the reference

Contains Nonbinding Recommendations

Draft – Not for Implementation

965 standard may be imperfect (e.g., sometimes includes a diagnostic error), are errors
966 made by the imperfect reference standard conditionally independent of errors
967 made by the ML-DSF, or are they positively correlated?
968 3.c.8. How will missing data be addressed in analysis?

969 **d. Performance targets**

970 3.d.1. What are the acceptance criteria?
971 3.d.2. What clinical considerations were used to develop the acceptance criteria?
972 3.d.3. How will the acceptance criteria support that the modification will be successfully
973 implemented?

974 **e. Additional testing needs**

975 3.e.1. Is database testing sufficient to address the risks associated with the proposed
976 modification (e.g., does the user need to interact with the device to evaluate the
977 performance or address a clinical risk or, for software that is part of a hardware
978 device,⁸³ how is the effect of the modification on hardware functionality
979 evaluated)?
980 3.e.2. How may clinical usability need to be addressed for a modification?
981

982 **(4) Update Procedures**

983 **a. Software verification and validation**

984 4.a.1. Does the proposed modification necessitate a different software verification and
985 validation plan from that used for the version of the device without any
986 modifications implemented?
987 4.a.2. What type of testing will be performed? Will the modified device be validated to
988 function in an integrated environment?
989 4.a.3. If the device includes other device functions in addition to the ML-DSF, how will
990 the impact of modifications to the ML-DSF on the other device functions be
991 evaluated?
992 4.a.4. If the device includes “other functions” in addition to the ML-DSF, how will the
993 “other functions” impact on the safety or effectiveness of the modified ML-DSF
994 be evaluated?

995 **b. When and how updates will be implemented**

996 4.b.1. How will the decision be made on when to perform an update? What is the
997 expected timeline for implementing the modifications? Is there a set frequency of
998 updates?
999 4.b.2. When and how will an update be implemented (e.g., automatically when the
1000 device is not being used, manually by users or hospital technicians, or both

⁸³ For the purposes of this guidance, “part of a hardware device” means the software is used to control a device, or the software is necessary for a hardware device to achieve its intended use.

Contains Nonbinding Recommendations

Draft – Not for Implementation

- 1001 manually and automatically)? What is the basis on which the mechanism of
1002 implementation is dependent?
- 1003 4.b.3. For ML-DSF updates to reusable medical equipment, how will the device
1004 operation, including function of critical safety features (e.g., medical device
1005 alarms), be verified following the update?
- 1006 4.b.4. Will updates be made globally (i.e., the same update applied to all devices in the
1007 field) or locally (e.g., the devices may be modified for a patient/provider/care
1008 unit/hospital)?
- 1009 4.b.5. What cybersecurity protocols⁸⁴ will be applied during updates?
- 1010 **c. Communication and transparency to users**
- 1011 4.c.1. How will the PCCP be described in the public summary document and/or
1012 labeling?
- 1013 4.c.2. How will updates be communicated to users, including, but not limited to, in
1014 updated labeling (e.g., release notes)?
- 1015 4.c.3. What information about modifications to the device (e.g., performance) will be
1016 communicated to the user?
- 1017 4.c.4. How will version information be presented to the user when reviewing device
1018 outputs?
- 1019 4.c.5. Will users have the option to review labeling before implementing an update?
- 1020 4.c.6. How will any known biases or other performance issues with the potential to
1021 result in individual or social harms be disclosed, including, but not limited to, in
1022 labeling?
- 1023 4.c.7. How will any changes in performance related to known issues or sources of bias
1024 be communicated to the user, including, but not limited to, in labeling?
- 1025 4.c.8. What information about the population and methods for validation will be
1026 provided?
- 1027 4.c.9. If patient data from previous device use is available and can be rerun on an
1028 updated ML model, will this activity be performed for the available data and will
1029 those updated results be available to patients and users? Is there a plan to
1030 communicate if patient results before and after an update would provide clinically
1031 meaningful differences?
- 1032 **d. Device monitoring plan**
- 1033 4.d.1. How will adverse events be tracked for different updates?
- 1034 4.d.2. Is there a plan to monitor real-world device performance (beyond general
1035 controls) and, if not, why is it not necessary?
- 1036 4.d.3. How will changes in performance in patient subpopulations be identified?

⁸⁴ For recommendations related to cybersecurity, please consult FDA guidance documents on this topic, including “Content of Premarket Submissions for Management of Cybersecurity in Medical Devices” (available at <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/content-premarket-submissions-management-cybersecurity-medical-devices>) and “Postmarket Management of Cybersecurity in Medical Devices” (available at <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/postmarket-management-cybersecurity-medical-devices>).

Contains Nonbinding Recommendations

Draft – Not for Implementation

- 1037
1038
1039
1040
1041
1042
1043
1044
1045
- 4.d.4. What will be the response to the identification of previously unknown risks or previously unrecognized high-risk patient subpopulations?
 - 4.d.5. What is the strategy to respond to unexpected performance deficiencies or other hazards, or to higher levels of adverse events, as compared with previous iterations of the device?
 - 4.d.6. How will errors in diagnosis (i.e., misdiagnosis), attributable or partially attributable to the device that do not meet the criteria for an adverse event, be tracked?

DRAFT

1046 **Appendix B: Example ML-DSF Scenarios Employing**
1047 **PCCPs**

1048 The examples in this appendix illustrate different ML-DSF scenarios where a PCCP could be
1049 employed. Due to the complexity of ML-DSFs, all examples are hypothetical and do not reflect
1050 any specific authorized device.

1051
1052 Each example begins with a brief description of an authorized device, its intended use, and one
1053 summary of a modification from the Description of Modifications in its authorized PCCP (in the
1054 examples, denoted as “Brief Overview of Pre-Specified Modification”). Please note that the
1055 provided summaries of the devices and modifications in this appendix are *not* intended to reflect
1056 the complete content or detail expected in a Description of Modifications section in a PCCP.
1057 Rather, proposed modifications should be described in much greater detail in a PCCP, consistent
1058 with the recommendations provided throughout this guidance. The post-authorization
1059 modification scenarios are described to illustrate how the PCCP would be implemented. A
1060 distinction is drawn between post-authorization modifications that 1) would be acceptable for the
1061 authorized device with a PCCP and could be implemented without a new marketing submission
1062 or 2) would not be acceptable for the authorized device with a PCCP and likely requires a new
1063 marketing submission⁸⁵ before the device could be introduced into interstate commerce.

1064
1065 Due to the complexity of ML-DSFs, it is not practical to describe all relevant considerations, or a
1066 complete PCCP, for the limited examples presented below. Therefore, while these examples
1067 highlight important concepts that could inform the development and utility of a PCCP, the PCCP
1068 will be specific to the circumstances of a particular ML-DSF, based on factors including a
1069 scientifically valid assessment of benefits and risks.

1070
1071 FDA recommends that the PCCP strategy be discussed with the appropriate FDA review division
1072 through the Q-Submission program⁸⁶ prior to submitting a marketing submission containing a
1073 PCCP. As part of a marketing submission, the manufacturer should provide a PCCP, consisting
1074 of a Description of Modifications (Section VI), a Modification Protocol (Section VII), and an
1075 Impact Assessment (Section VIII).

1076
1077 **(1) Patient Monitor Software**

1078
1079 **Background:**

1080
1081 The device is an ML-DSF intended for use in high-acuity healthcare environments (e.g., an
1082 intensive care unit). The software obtains physiological signals (e.g., electrocardiogram, blood
1083 pressure, pulse oximetry) from a primary patient monitor. The physiological signals are

⁸⁵ 21 CFR 807.81(a)(3) or 21 CFR 814.39(a).

⁸⁶ See FDA’s guidance “Requests for Feedback and Meetings for Medical Device Submissions: The Q-Submission Program” available at <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/requests-feedback-and-meetings-medical-device-submissions-q-submission-program>.

Contains Nonbinding Recommendations

Draft – Not for Implementation

1084 processed and analyzed by an ML model to detect patterns that occur at the onset of physiologic
1085 instability. When physiologic instability is detected, an audible alarm signal is generated to
1086 indicate that prompt clinical action is needed to prevent potential harm to the patient. The ML-
1087 enabled medical device was authorized with a PCCP.

1088

Brief Overview of Pre-Specified Modification:

1090

1091 The manufacturer would like to re-train the ML model with more data to reduce the false alarm
1092 rate while maintaining or increasing sensitivity to the onset of physiologic instability. The
1093 baseline sensitivity is $y\%$. The manufacturer would like to demonstrate a significant
1094 improvement in the false-alarm rate while the sensitivity remains within a pre-specified
1095 non-inferiority margin of $z\%$ when compared with the original device, i.e., the version of the
1096 device without any modifications.⁸⁷

1097

1098

Post-Authorization Modification Scenarios:

1099

1100

1101 *Modification Scenario 1: Modification related to quantitative measures of device performance,*

1102 *as specified in the PCCP, and implemented in accordance with the PCCP*

1103

1104

1105

1106

1107

1108

1109

1110

1111

1112

1113

1114

1115

1116

1117

1118

1119

1120

1121

1122

1123

1124

1125

In accordance with the Modification Protocol, data were collected and used to re-train the ML model. The modified ML model was tested per the methods specified in the Modification Protocol. The results demonstrated that the false alarm rate was significantly reduced while the mean sensitivity estimate was statistically within the proposed non-inferiority margin of the baseline sensitivity $y\%$. Labeling was updated in accordance with the modified ML-DSF performance, and communication was provided to the device users. Because the device modification was specified in the PCCP, and it was implemented in conformance with the PCCP, the device modification would not require a new marketing submission. The manufacturer should document the modification that was specified in the PCCP in accordance with their quality system.

Modification Scenario 2: Modification beyond quantitative measures of device performance, which was not specified in the PCCP

In accordance with the Modification Protocol, the manufacturer re-trained their ML model using additional data to improve the sensitivity. Analytical validation demonstrated that the revised ML model has the same false alarm rate and sensitivity as the previous version. However, the manufacturer also noticed that the modified ML model maintained the same sensitivity and can now also predict physiologic instability in advance of its onset, which the previous version of the ML model could not do. The manufacturer would like to update the device's indications for use to reflect this additional performance claim to predict physiologic instability in advance of its onset,

⁸⁷ The values in this example are shown as variable terms. A completed PCCP should include specific criteria whenever possible.

Contains Nonbinding Recommendations

Draft – Not for Implementation

1126 which was not previously included in the PCCP. The methods used for analysis,
1127 performance, and statistics were not specified in the PCCP for predicting a future state.
1128 Because this modification that was not included in the PCCP could significantly affect
1129 the safety or effectiveness of the device, a new marketing submission would be required.
1130

1131 **(2) Skin Lesion Software**

1132 **Background:**

1133 The device is an ML-DSF that analyzes images of skin lesions by identifying and characterizing
1134 its features (e.g., color, quantification of area change over time) to aid in diagnosis. It was
1135 validated with a specific camera and is intended to be used by a primary healthcare provider. The
1136 device was authorized with a PCCP.
1137

1138 **Brief Overview of Pre-Specified Modification:**

1139 The manufacturer would like to extend the ML-DSF for use on additional general-purpose
1140 computing platforms, including smartphones and tablets. The general-purpose computing
1141 platform must include a two-dimensional camera that meets the minimum specifications defined
1142 in the PCCP. The updated device must achieve a minimum performance defined in the
1143 Modification Protocol using a specified methodology.
1144

1145 **Post-Authorization Modification Scenarios:**

1146 *Modification Scenario 1: Modification in input, as specified in the PCCP and implemented in
1147 accordance with the PCCP*

1148 The manufacturer's analytical validation demonstrated the ML-DSF can be deployed on
1149 two additional smartphones that have image acquisition specifications that meet the
1150 minimum specifications provided in the PCCP. The analytical performance using the new
1151 image acquisition systems was found to be statistically equivalent to the baseline
1152 performance, as specified in the Modification Protocol. Labeling was updated to reflect
1153 the new ML-DSF compatibility with the additional smartphones, which may increase
1154 access of the ML-DSF in the healthcare community. Communication updates on device
1155 compatibility were also provided. Because the device modification was specified in the
1156 PCCP, and it was implemented in conformance with the PCCP, the device modification
1157 would not require a new marketing submission. The manufacturer should document the
1158 modification that was specified in the PCCP in accordance with their quality system.
1159

1160 *Modification Scenario 2: Modification in input that was not specified in the PCCP*

1161 The manufacturer would like to deploy a modified ML model that uses images captured
1162 by a thermographic camera; however, the new camera technology was not specified in
1163 the PCCP. Because this modification that was not included in the PCCP could
1164

Contains Nonbinding Recommendations

Draft – Not for Implementation

1170 significantly affect the safety or effectiveness of the device, a new marketing submission
1171 would be required.

1172
1173 *Modification Scenario 3: Modification related to the device's use and performance, which was*
1174 *not specified in the PCCP*

1175
1176 The manufacturer would like to distribute a new version of the ML-DSF that is patient-
1177 facing. The ML-DSF would provide an analysis of the physiological characteristics of
1178 skin lesions, as it does currently, and direct patients to follow-up with a dermatologist
1179 based on the preliminary analysis of the malignancy of the skin lesion. The modification
1180 introduces many new, unconsidered risks that were not yet mitigated in the current
1181 PCCP, given that the modified ML-DSF will be patient-facing. Because this modification
1182 that was not included in the PCCP could significantly affect the safety or effectiveness of
1183 the device, a new marketing submission would be required.

1184

1185 **(3) Ventilator Settings Software**

1186

1187 **Background:**

1188

1189 The device is an ML-DSF intended for use in the healthcare or home-use setting. The ML-DSF
1190 recommends the ideal ventilation parameters based on input data interpretation, which can then
1191 be programmed into the ventilator by a healthcare provider. The manufacturer proposes
1192 modifications to the ML-DSF to improve performance within the original indications. The
1193 device was authorized with a PCCP.

1194

1195 **Brief Overview of Pre-Specified Modification:**

1196

1197 The manufacturer would like to re-train the ML model to optimize site-specific performance for
1198 a specific subset of patients with a particular condition, for whom sufficient data were not
1199 previously available. Specifically, the manufacturer would like to modify the ML model to
1200 improve its ability to optimize ventilator settings for minute volume and tidal volume to reduce
1201 the variability to $\pm x\%$ within the specified range to improve treatment outcomes for that subset
1202 of patients at different sites.

1203

1204 **Post-Authorization Modification Scenarios:**

1205

1206 *Modification Scenario 1: Modification related to the device's use and performance in a subset of*
1207 *the patient population, which was specified in the PCCP and implemented in accordance with*
1208 *the PCCP*

1209

1210 The manufacturer re-trained and re-validated the ML model on newly acquired data in a
1211 subpopulation of patients with a particular disorder. As evidenced by additional clinical
1212 performance data collected and analyzed per the Modification Protocol, the re-training on
1213 new data improved the reliability and precision of ventilator setting recommendations,

Contains Nonbinding Recommendations

Draft – Not for Implementation

1214 showing improvements and specializations to improve site-specific ventilator operation.
1215 The updated recommendations were validated against patient outcomes and adverse
1216 events that may occur due to ventilator setting inaccuracies following the methods in the
1217 Modification Protocol. The adverse event rates and outcomes acceptance criteria were
1218 established in the Modification Protocol, and as such, were used to validate the updated
1219 ML model. The ML-DSF was updated to implement the re-trained ML model and the
1220 labeling was updated for clarity to inform users how the updated ML model accounts for
1221 local experience and prevalence. The implementation of this modification was done only
1222 at applicable sites. Because this device modification was specified in the PCCP, and it
1223 was implemented in conformance with the PCCP, the device modification would not
1224 require a new marketing submission. The manufacturer should document the
1225 modification that was specified in the PCCP in accordance with their quality system.
1226

1227 *Modification Scenario 2: Modification related to device’s use and performance in a subset of the*
1228 *patient population, which was specified in the PCCP, but was not implemented in conformance*
1229 *with the PCCP*
1230

1231 The manufacturer re-trained and re-validated the ML model on newly acquired data, but
1232 was unable to fulfill the protocol because the manufacturer had to implement a reference
1233 standard that was different from the one described in the Modification Protocol. Even
1234 though the modification was specified in the PCCP, it was not implemented in
1235 conformance with the PCCP. Because this modification that was not implemented in
1236 conformance with the PCCP could significantly affect the safety or effectiveness of the
1237 device, a new marketing submission would be required.
1238

1239 **(4) Image Acquisition Assistance Device**

1240 **Background:**

1241 The ML-DSF is integrated into an imaging system and is intended to assist healthcare providers
1242 during acquisition of ultrasound images of the shoulder region in adult and pediatric populations
1243 by highlighting portions of the image where it detects a potential abnormality in real time. The
1244 ML-DSF interfaces with the device acquisition system, analyzes its output using an ML model,
1245 provides real-time alerts to the operator if an abnormality is detected, and automatically adjusts
1246 parameters in the device acquisition system during image acquisition to optimize the imaging.
1247 The device does not provide a diagnosis. The ML-enabled medical device was authorized with a
1248 PCCP.

1249 **Brief Overview of Pre-Specified Modification:**

1250 The manufacturer would like to re-train their ML model to further optimize the accuracy of the
1251 abnormality detection. The PCCP pre-specifies that both the sensitivity and specificity will be
1252 shown to be significantly superior for abnormality identification during the shoulder exam.

Contains Nonbinding Recommendations

Draft – Not for Implementation

1253 **Post-Authorization Modification Scenario:**

1254 *Modification Scenario 1: Modification related to quantitative measures of device performance,*
1255 *as specified in the PCCP, and implemented in accordance with the PCCP*

1256 In accordance with the Modification Protocol, imaging data were collected and used to
1257 re-train the ML model. The modified ML model was tested according to a specified test
1258 protocol in the Modification Protocol. The results demonstrated that the sensitivity and
1259 specificity for abnormality identification met statistical superiority pre-specifications.
1260 Labeling was updated in accordance with the modified device performance, and
1261 communication was provided to the device users. Because the device modification was
1262 specified in the PCCP, and because it was implemented in conformance with the PCCP,
1263 the device modification would not require a new marketing submission. The
1264 manufacturer should document the modification that was specified in the PCCP in
1265 accordance with their quality system.

1266 *Modification Scenario 2: Modification related to the device's use and performance that was not*
1267 *specified in the PCCP*

1268 The manufacturer used new images to re-train the ML model and would like to update
1269 their labeling to reflect improved performance in the same shoulder region in a subset of
1270 the pediatric patient population identified in the device's indications for use. However,
1271 the modification was not specified in the PCCP. Because this modification that was not
1272 included in the PCCP could significantly affect the safety or effectiveness of the device, a
1273 new marketing submission would be required.
1274

1275 **(5) Feeding Tube Placement Radiograph Analysis Software**

1276 **Background:**

1277 The device is an ML-DSF that analyzes chest radiographs from hospitalized patients to evaluate
1278 feeding tube placement. The ML-DSF reorders the radiologist's review queue so that
1279 radiographs identified as having a higher likelihood of feeding tube misplacement are placed
1280 higher in the queue. The device was authorized with a PCCP.
1281
1282
1283

1284 **Brief Overview of Pre-Specified Modification:**

1285 The manufacturer would like to improve ML model performance by increasing sensitivity to
1286 misplaced feeding tubes by re-training on new data. The baseline sensitivity is x%.

1287 Additionally, the manufacturer would like to modify the device so that it would notify nursing
1288 staff to check on the patient, in parallel with prioritization in the review queue. This modification
1289 requires achieving a sensitivity of z%.
1290
1291
1292

Contains Nonbinding Recommendations

Draft – Not for Implementation

1293 **Post-Authorization Modification Scenarios:**

1294

1295 *Modification Scenario 1: Modification related to quantitative measures of device performance,*
1296 *and modification related to device's use and performance, which were both specified in the*
1297 *PCCP and implemented in accordance with the PCCP*

1298

1299

1300

1301

1302

1303

1304

1305

1306

1307

1308

1309

The manufacturer re-trained and re-validated the ML model on newly acquired data as described in the Modification Protocol, which significantly improved the ML-DSF sensitivity from x% to z% to detect incorrect feeding tube placements. The improved sensitivity achieved the required sensitivity (z%) statistically to enable the nursing staff notification function, and that notification function was enabled. Labeling of the device was changed in accordance with the PCCP. Because the device modification was specified in the PCCP, and it was implemented in conformance with the PCCP, the device modification would not require a new marketing submission. The manufacturer should document the modification that was specified in the PCCP in accordance with their quality system.

1310

1311

1312

Modification Scenario 2: Modification related to device's use and performance that was not specified in the PCCP

1313

1314

1315

1316

1317

1318

1319

1320

The manufacturer used the same database of images to re-train the ML model to identify pneumonia on chest radiographs. The pneumonia identification function was found to have the same sensitivity and specificity as the feeding tube ML model. The manufacturer would like to employ the new pneumonia identification function feature alongside the feeding tube placement ML model in radiograph triage. The modification was not specified in the PCCP. Because this modification that was not included in the PCCP could significantly affect the safety or effectiveness of the device, a new marketing submission would be required.